A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

NCT02972840 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

635

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Mantle Cell

Interventions

DRUG: Acalabrutinib
DRUG: Bendamustine
DRUG: Rituximab
DRUG: Placebo

Sponsor

Acerta Pharma BV

Collaborators

[object Object]